Special Drug Use Investigation of EYLEA for CRVO
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Central retinal vein occlusion
- Focus Adverse reactions
- Acronyms JPMS-CRVO
- Sponsors Bayer
- 17 Mar 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019 as per ClinicalTrails.gov record.
- 18 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Nov 2015 Planned End Date changed from 1 Sep 2020 to 1 Nov 2018 as reported by ClinicalTrail.gov record.